NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 04:00PM ET
1.18
Dollar change
+0.05
Percentage change
4.42
%
Index- P/E- EPS (ttm)-0.64 Insider Own5.00% Shs Outstand23.85M Perf Week-2.48%
Market Cap28.14M Forward P/E- EPS next Y-0.59 Insider Trans0.00% Shs Float22.66M Perf Month25.49%
Enterprise Value7.98M PEG- EPS next Q-0.15 Inst Own14.05% Short Float0.33% Perf Quarter16.83%
Income-14.33M P/S- EPS this Y9.77% Inst Trans-48.60% Short Ratio1.10 Perf Half Y2.61%
Sales0.00M P/B1.36 EPS next Y-1.54% ROA-52.02% Short Interest0.08M Perf YTD0.85%
Book/sh0.86 P/C1.36 EPS next 5Y-6.46% ROE-60.35% 52W High1.76 -32.95% Perf Year-14.49%
Cash/sh0.87 P/FCF- EPS past 3/5Y3.33% 7.57% ROIC-68.57% 52W Low0.81 45.66% Perf 3Y-75.16%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility6.60% 7.39% Perf 5Y-80.88%
Dividend TTM- EV/Sales- EPS Y/Y TTM53.82% Oper. Margin- ATR (14)0.08 Perf 10Y-99.64%
Dividend Ex-Date- Quick Ratio7.20 Sales Y/Y TTM- Profit Margin- RSI (14)62.51 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio7.20 EPS Q/Q34.28% SMA2010.62% Beta0.77 Target Price10.00
Payout- Debt/Eq0.02 Sales Q/Q- SMA5015.18% Rel Volume2.06 Prev Close1.13
Employees36 LT Debt/Eq0.01 EarningsMay 23 SMA2002.06% Avg Volume68.44K Price1.18
IPOJul 31, 2014 Option/ShortYes / Yes EPS/Sales Surpr.0.00% - Trades Volume141,087 Change4.42%
Date Action Analyst Rating Change Price Target Change
Mar-02-21Reiterated H.C. Wainwright Buy $22 → $33
Jun-10-25 08:30AM
May-20-25 08:00AM
Apr-23-25 08:30AM
Apr-22-25 06:17AM
Apr-21-25 08:30AM
08:00AM Loading…
Apr-03-25 08:00AM
Mar-17-25 08:00AM
Mar-04-25 04:30PM
Mar-03-25 08:22AM
Feb-18-25 06:20AM
Feb-11-25 02:30PM
Jan-10-25 09:00AM
Dec-12-24 11:29AM
Dec-11-24 08:30AM
Dec-05-24 10:49AM
08:30AM Loading…
Dec-03-24 08:30AM
Nov-26-24 10:15AM
10:15AM
Nov-22-24 12:25PM
Nov-20-24 08:00AM
Nov-14-24 08:00AM
Nov-12-24 08:00AM
Oct-31-24 12:00PM
Oct-30-24 08:00AM
Sep-26-24 08:30AM
Sep-24-24 08:30AM
Sep-11-24 12:00PM
Aug-30-24 09:00AM
Jul-23-24 08:00AM
Jul-19-24 09:00AM
08:00AM Loading…
Jun-24-24 08:00AM
Jun-20-24 08:00AM
Jun-17-24 08:00AM
Jun-03-24 08:00AM
May-29-24 04:15PM
May-28-24 08:12AM
Apr-29-24 08:00AM
Apr-22-24 08:00AM
Apr-16-24 07:50AM
Apr-15-24 01:01PM
Apr-11-24 02:58PM
08:05AM
Apr-05-24 07:52AM
Mar-22-24 10:50AM
Feb-26-24 08:30AM
Feb-21-24 08:30AM
Feb-07-24 08:00AM
Jan-17-24 08:00AM
Dec-20-23 08:00AM
Nov-21-23 07:00AM
Sep-11-23 08:00AM
Sep-07-23 08:00AM
Aug-02-23 08:00AM
Jul-31-23 08:00AM
Jun-26-23 08:00AM
Jun-06-23 08:00AM
May-31-23 08:04AM
May-08-23 08:00AM
Apr-20-23 10:18AM
Apr-19-23 08:00AM
Apr-17-23 08:00AM
Apr-14-23 09:40AM
Apr-12-23 10:45AM
Apr-10-23 03:07AM
Apr-04-23 08:00AM
Apr-03-23 08:00AM
Mar-20-23 08:00AM
Feb-23-23 08:00AM
Feb-15-23 08:00AM
Jan-25-23 08:37AM
Jan-04-23 08:00AM
Dec-05-22 08:00AM
Dec-02-22 08:00AM
Dec-01-22 02:00PM
Nov-28-22 08:00AM
Nov-15-22 08:00AM
Nov-11-22 09:05AM
Nov-10-22 08:00AM
Oct-03-22 08:13AM
Sep-13-22 08:00AM
Sep-12-22 08:00AM
Sep-06-22 08:00AM
Aug-29-22 08:00AM
Aug-24-22 08:00AM
Aug-22-22 08:00AM
Aug-17-22 08:00AM
Aug-03-22 08:15AM
Jul-12-22 09:05AM
Jul-06-22 08:37AM
Jun-07-22 08:00AM
Jun-06-22 08:00AM
Jun-04-22 09:45AM
May-31-22 08:00AM
May-25-22 08:00AM
May-23-22 08:00AM
May-19-22 08:00AM
May-10-22 08:00AM
May-09-22 09:05AM
May-05-22 08:37AM
May-02-22 08:00AM
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.